Calpain Therapeutics is a privately-held venture dedicated to bringing to market a set of proprietary chemical compounds that effectively and selectively inhibit Calpain – a family of cysteine proteases which are present in the cytoplasma of many tissues. Calpain Therapeutics aims to bring to market new chemical entities that dramatically slow the progression of ophthalmic and neurodegenerative related diseases caused by Calpain.